Massachusetts-backed Isis Pharmaceuticals receives $3.5m milestone payment from Biogen for battle against spinal muscular atrophy.
Isis Pharmaceuticals has been awarded a $3.5m milestone payment from Biogen Idec after the firm’s success in dosing its first patient with a treatment aimed at curing infants with spinal muscular atrophy (SMA). The Calif.-based firm uses intellectual property licensed from the University of Massachusetts Medical School, as well as IP developed at research centre…
The rest of this content is only accessible to Global Venturing Subscribers.
This content is only accessible to subscribers. If you are a subscriber, please sign in. Otherwise, if you would like to try before you buy and haven't previously taken out a free trial, you can do so below. You can also see details on subscriptions by clicking the Subscription Options button.
